SFDA To Investigate Ins And Outs Of API Sector
This article was originally published in PharmAsia News
China’s State FDA will conduct investigations into the API sector, focusing on areas including API generic names, API approval codes, export regions, and EU pharma certification.
You may also be interested in...
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.